These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 12360156)
1. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Kereiakes DJ; Montalescot G; Antman EM; Cohen M; Darius H; Ferguson JJ; Grines C; Karsch KR; Kleiman NS; Moliterno DJ; Steg PG; Teirstein P; Van de Werf F; Wallentin L Am Heart J; 2002 Oct; 144(4):615-24. PubMed ID: 12360156 [TBL] [Abstract][Full Text] [Related]
2. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. Singh KP; Roe MT; Peterson ED; Chen AY; Mahaffey KW; Goodman SG; Harrington RA; Smith SC; Gibler WB; Ohman EM; Pollack CV; J Thromb Thrombolysis; 2006 Jun; 21(3):211-20. PubMed ID: 16683212 [TBL] [Abstract][Full Text] [Related]
4. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G; Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196 [TBL] [Abstract][Full Text] [Related]
5. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes. Bosanquet N; Jönsson B; Fox KA Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436 [TBL] [Abstract][Full Text] [Related]
6. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD; JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194 [TBL] [Abstract][Full Text] [Related]
7. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
8. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305 [TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Salam AM Expert Opin Investig Drugs; 2003 Sep; 12(9):1567-70. PubMed ID: 12943500 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845 [TBL] [Abstract][Full Text] [Related]
11. Antiplatelet intervention in acute coronary syndrome. Arora RR; Rai F Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648 [TBL] [Abstract][Full Text] [Related]
12. Managing acute coronary syndrome: evidence-based approaches. Spinler SA Am J Health Syst Pharm; 2007 Jun; 64(11 Suppl 7):S14-24. PubMed ID: 17519441 [TBL] [Abstract][Full Text] [Related]
13. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. Wong GC; Giugliano RP; Antman EM JAMA; 2003 Jan; 289(3):331-42. PubMed ID: 12525234 [TBL] [Abstract][Full Text] [Related]